Project: Serenity Pharmaceuticals
Status: Completed 2017
Description: Heights principals founded Serenity Pharmaceuticals in 2005 and successfully brought the drug through FDA approval. The drug named Noctiva, licensed by Avadel in 2017 is the first and only FDA approved product for nocturia due to nocturnal polyuria. Nocturnal polyuria is the overproduction of urine at night and leads to the condition of nocturia which causes patients to wake two or more times per night to void. Estimates show that nocturia affects approximately 40 million people in the U.S. and represents a large unaddressed and unmet medical need.
Noctiva is the first and only formulation of desmopressin acetate, a vasopressin analog approved by the FDA for the treatment of nocturia. It is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected preservative-free intranasal delivery system.
Noctiva is now available to patients. More information is available at www.noctivahcp.com